[1 Name of Reporting Person Barron Partners LP I.R.S. Identification No. of Above Person 43-1981699 2 Check the Appropriate Box if a Member of a Group (a) [ ] (b) [ ] 3 SEC Use Only 4 Source of Funds WC Items 2(d) or 2(e) [ ] 6 Citizenship or Place of Organization Delaware Number of 7 Sole Voting Power]
[Skystar Bio-Pharmaceutical Awarded High Technology Enterprise Certificate Preferentialome Tax Rate Extended through 2011 XI'AN, CHINA, September 2, 2009ystar Bio-Pharmaceuticalmpany High Technology Enterprise Certificates are awarded to qualified enterprises that meet the following criteria: developingre intellectual property rights, receiving over 60% of their annual revenues from high-technology products/services, and perform highly technical research and development.ystar initially]
[Skystar Bio-Pharmaceutical Awarded High Technology Enterprise Certificate Preferentialome Tax Rate Extended through 2011 XI'AN, CHINA, September 2, 2009ystar Bio-Pharmaceuticalmpany High Technology Enterprise Certificates are awarded to qualified enterprises that meet the following criteria: developingre intellectual property rights, receiving over 60% of their annual revenues from high-technology products/services, and perform highly technical research and development.ystar initially]
[SCHEDULE 13D/A (Amendment 1)ystar Bio-Pharmaceuticalmpany (Name of Issuer)mmon Stock (Title of Class of Securities) 830884201 (CUSIP Number) Rebecca Baum 730 FIFTH AVENUE, 25TH FLOOR NEW YORK, NY 10019 212-359-0204 (Name,dress and Telephone Number of Person Authorized to Receive Notices andmmunications) August 25, 2009 (Date of Event which Requires Filing of this Statement) If the filing]
[SCHEDULE 13D/A (Amendment 1)ystar Bio-Pharmaceuticalmpany (Name of Issuer)mmon Stock (Title of Class of Securities) 830884201 (CUSIP Number) Rebecca Baum 730 FIFTH AVENUE, 25TH FLOOR NEW YORK, NY 10019 212-359-0204 (Name,dress and Telephone Number of Person Authorized to Receive Notices andmmunications) August 25, 2009 (Date of Event which Requires Filing of this Statement) If the filing]
[FORM 10-Q þ For the quarterly period ended June 30, 2009 or o For the transition period from Skystar Bio-Pharmaceutical Company (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer EX-32.1 5 v156959_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v156959_ex32-2.htm]
[FORM 10-Q þ For the quarterly period ended June 30, 2009 or o For the transition period from Skystar Bio-Pharmaceutical Company (Exact name of small business issuer as specified in its charter) Nevada (State or other jurisdiction of incorporation or organization) 33-0901534 (I.R.S. employer identification number) Room 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian Province, P.R. China] [CERTIFICATION I, Weibing Lu, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period] [CERTIFICATION I, Bennet T. Tchaikovsky, certify that: 1. I have reviewed this Quarterly 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Weibing Lu Weibing Lu Chief Executive Officer EX-32.1 5 v156959_ex32-1.htm] [CERTIFICATION (1) (2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company at the dates and for the periods indicated. Bennet P. Tchaikovsky Chief Financial Officer (Principal Financial and Accounting Officer) EX-32.2 6 v156959_ex32-2.htm]
[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA – August 14, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS § Revenues increased 39.4% year-over-year to $6.2 million § Gross margin improved to 52.6% from 51.6% in the second quarter of 2008 § Income from operations increased by 37.6% year-over-year to $1.7 million § Began]
[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA – August 14, 2009 – Skystar Bio-Pharmaceutical Company (NASDAQ: SKBI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS § Revenues increased 39.4% year-over-year to $6.2 million § Gross margin improved to 52.6% from 51.6% in the second quarter of 2008 § Income from operations increased by 37.6% year-over-year to $1.7 million § Began]
[Skystar Bio-Pharmaceutical Announces Second Quarter 2009 Results XI'AN, CHINA August 14, 2009ystar Bio-Pharmaceuticalmpany (NASDAQ:BI) SECOND QUARTER 2009 & RECENT HIGHLIGHTS Revenuesreased 39.4% year-over-year to $6.2 million Gross margin improved to 52.6% from 51.6% in the second quarter of 2008ome from operationsreased by 37.6% year-over-year to $1.7 million]
